

# Results of Operations

for financial year ended December 31 2024

 **株式会社 EMシステムズ**

TSE Prime Section:4820

These documents have been translated from Japanese originals for reference Purposes only.  
In the event of any discrepancy between these translated documents and the Japanese originals, the originals shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translations.

1. Topics
2. Performance Overview (FY2024.12)
3. Status by Segment (FY2024.12)
4. Company Initiatives
5. Fiscal Year Forecast (FY2025.12)
6. Shareholder Returns
7. Appendix.

# Topics

## FY2024.12

Introduction of welfare administration-related products greatly drove results  
Options related to Electronic Prescriptions and Online eligibility verification increased significantly from those announced in Q3

Achieved all-time highs for all four major indicators (net sales, operating income, ordinary income, and net income)

The year-end dividend was 6 yen higher than at the time of the Q3 revision,  
Annual dividends increased 2.5 times year on year to 35 yen (record high)  
Announced medium-term management plan in Q3 to achieve a dividend payout ratio of 100%

Mid-term Management Plan FY2025-FY2027

<https://emsystems.co.jp/english/pdf/mid-term-management-plan.pdf>

## FY2025.12 Forecasts

Under the medium-term management plan announced in November 2024  
Forecast of steady achievement  
Decrease in welfare administration-related sales in 2024

To ensure that the ROE targets in the medium-term management plan are achieved, we plan to pay an annual dividend of 35 yen, the same amount as in 2024  
An increase of 6 yen from the announcement of 29 yen in the medium-term management plan  
Dividend payout ratio is 130.5% of the EPS forecast of 26.82 yen



# Performance Overview

## FY2024.12

## FY2024.12 Consolidated results

Units:Millions of yen


	FY2023.12 Results	FY2024.12 Estimated results	FY2024.12 Results	Compared to previous year	Compared to estimated results
Sales	20,355	23,739	24,837	22.0%	4.6%
EBITDA	3,588	-	6,606	84.1%	-
Operating profits	2,330	3,797	4,464	91.6%	17.6%
Ordinary profits	2,869	4,501	5,184	80.7%	15.2%
Net income	1,962	1,978	2,425	23.6%	22.6%

## FY2024.12 Topics


Sales:	Achieved steady sales growth due to M&As of Good Cycle Systems Inc. and UNIKE SOFTWARE RESEARCH Co.,Ltd. Acceleration of establishment of welfare administration (Electronic Prescriptions and Online eligibility verification optional software)
EBITDA:	Significant growth due to the impact of accelerated installation of welfare administration (Electronic Prescriptions and Online eligibility verification optional software)
Operating profits:	Provision of special compensation to employees in line with the substantial increase in profits, sales promotion expenses for 2025, and one-time expenses due to system failures in the dispensing and medical departments amounted to 958 million yen
Net income:	Despite the full impairment of related assets in IT Systems for Clinics and IT Systems for Long-term care/welfare (1,440 million yen, 432 million yen for clinics, and 1,008 million yen for long-term care/welfare), net income increased year on year

\* EBITDA is calculated by adding back depreciation and amortization and one-time expenses such as special compensation for employees, sales promotion expenses, and system failures to operating income.

## Sales



## Operating profit ■ EBITDA



\* EBITDA is calculated by adding back depreciation and amortization and one-time expenses such as special compensation for employees, sales promotion expenses, and system failures to operating income.

# Status by Segment

## FY2024.12



# Sales / Operating Profits-Summary(By Segment)

In respect of welfare administration-related matters, including both the pharmacy and clinic segments, full-year results were approximately three times those of the initial forecast, Compared to the revised forecast announced on November 14, the period from October to December increased by 1.5 times

## IT Systems for Pharmacies

Sales

Sales of recurring income grew 13.4% year on year to 9,886 million yen due to M&As and an increase in the number of customers  
Initial sales increased significantly overall despite the end of the previous year's intensive demand for Online eligibility verification systems. This was due in part to a drop in sales related to Online eligibility verification mitigated by the acceleration of the installation of optional software (for a  $\Delta$  of 847 million yen), and to the effects of the m&a effects (an increase of 702 million yen) and an increase in sales of Electronic Prescriptions (an increase of 3,538 million yen)

Operating Profits

Despite the end of the intensive demand for Online eligibility verification systems., operating income increased significantly due to the accelerated installation of Electronic Prescriptions and Online eligibility verification optional software

## IT Systems for Clinics

Initial sales declined year-on-year, as the effects of the end of intensive demand for Online eligibility verification ( $\Delta$ : 386 million yen) were not offset by the increase (of 222 million yen) in Electronic Prescriptions sales  
Sales of recurring income decreased due to the temporary impact of in-house replacement of [Uni-Medical], for which support is scheduled to end, and system failures  
Although the impact of system failures was temporary, this was particularly a factor behind the decrease in recurring income sales in Q4 (the impact on sales ceased)

Operating losses increased due to the end of intensive demand for Online eligibility verification systems as well as to the effects of system failures and extraordinary compensation

## IT Systems for Long-term care/welfare

Initial sales increased due to the incorporation of [Sukoyaka Sun] in large-scale long-term care facilities  
While the number of "MAPs for NURSING CARE" licenses increased, billing sales remained stable due to strategic replacement of existing-products, but the number of users decreased slightly, resulting in a decrease in maintenance sales

Operating losses narrowed slightly due to the effects of fixed cost improvements resulting from impairments implemented in Q3

## Sales

Units:Millions of yen

	FY2023.12	FY2024.12	YoY change	YoY % change
Pharmacies	16,159	20,699	4,539	28.1%
Clinics	2,802	2,564	△238	△8.5%
long-term care/welfare	550	570	19	3.5%
Other	973	1,174	200	20.6%

## Operating profits


Units:Millions of yen

	FY2023.12	FY2024.12	YoY change	YoY % change
Pharmacies	2,939	5,255	2,316	78.8%
Clinics	△130	△423	△293	-
long-term care/welfare	△540	△450	90	-
Other	48	60	11	24.8%

\* Sales and operating profits by segment are the amounts before elimination of inter-segment transactions.

## Increase/Decrease in Initial sales


Units : Millions of yen



\* Categories of increases/decreases are the amounts before applying revenue recognition standards

## Increase/Decrease in Initial sales

Units : Millions of yen




\* Categories of increases/decreases are amounts before considering increase/decrease of consolidated subsidiaries


In Q4, the number of customers for both pharmacies and clinics increased slightly, and ARPU remained stable. We aim to improve ARPU in our efforts in 2025.

## IT Systems for Pharmacies

Number of customers\*1




ARPU\*2



## IT Systems for Clinics

Number of customers\*1




\*1 Number of consolidated customers

\*2 ARPU(Average Revenue Per User) is calculated by [Individual (monthly billing sales + monthly maintenance sales)/Number of customers in the target period]

# Company Initiatives


## Market environment




While demand for medical and long-term care/welfare services will increase in line with the 2025 problem (Japan's falling birthrate and aging of the population), there is an urgent need to secure medical and long-term care/welfare practitioners and improve operational efficiency



An increase in cyberattacks on medical organizations making cybersecurity measures and responses mandatory\*1




Increase in the number of large-scale chain long-term care facilities due to the aging of society  
To response to [Care Plan Data Linkage System] and LIFE support\*2  
Improve data accuracy




Due to an industry-wide outbreak of drug mislabeling on electronic prescriptions, the Ministry of Health, Labor and Welfare requests simultaneous inspections of 44,000 medical institutions and pharmacies nationwide.


## Initiatives




Development of unique solutions that leverage the characteristics of our business as an all-in-one services provider for pharmacies, clinics, and long-term care/welfare  
On the website EM-AVALON specializing in the medical and long-term care/welfare fields  
Enhanced content, provision of online seminars for medical practitioners, etc.



Development of solutions designed to resolve industry issues such as labor shortages and operational efficiency (Ex: prescription sharing systems, prescription readers, etc.)



Participation in the government-promoted electronic medical record standardization verification project



OEM provision of our infrastructure systems and applications to other companies


 Clinics  Pharmacies  Long-term care/welfare

\*1 Ministerial Ordinance Partially Revising the Ordinance for Enforcement of the Medical Care Act(March 10, 2023 Ministry of Health, Labor and Welfare)

\*2 LIFE : Long-term care Information system For Evidence

## Performance Targets

Units: Millions of yen



## Business Strategy


	Pharmacies	Clinics	Long-term care/welfare
Segment strategy	Expand market share of wallets	Market share Expand	Achieve profitability
Enhancement of Business Foundation	Establishment of a sustainable system		
	Further promotion of human capital management		
	Improvement of capital efficiency		



# FY2025-FY2027 Medium-term Management Plan - 2

(millions of yen)	FY2024.12 Results	FY2025.12 Plan	FY2026.12 Plan	FY2027.12 Plan
<b>Sales</b>	<b>24,837</b>	<b>21,740</b>	<b>22,762</b>	<b>23,511</b>
<b>Year-on-year growth rate</b>	<b>22.0%</b>	<b>Δ12.5%</b>	<b>4.7%</b>	<b>3.3%</b>
IT Systems for Pharmacies	20,699	17,798	18,658	19,074
IT Systems for Clinics	2,564	2,321	2,403	2,656
IT Systems for Long-term care / welfare	570	677	752	833
Other	1,174	1,120	1,125	1,125
Adjustment	Δ171	Δ178	Δ178	Δ178
<b>EBITDA</b>	<b>6,606</b>	<b>3,436</b>	<b>4,361</b>	<b>5,023</b>
<b>Operating profits</b>	<b>4,464</b>	<b>2,522</b>	<b>3,316</b>	<b>4,031</b>
<b>Operating margin</b>	<b>18.0%</b>	<b>11.6%</b>	<b>14.6%</b>	<b>17.1%</b>
<b>Year-on-year growth rate</b>	<b>91.6%</b>	<b>Δ43.5%</b>	<b>31.5%</b>	<b>21.5%</b>
IT Systems for Pharmacies	5,255	3,062	3,553	3,944
IT Systems for Clinics	Δ423	Δ431	Δ196	8
IT Systems for Long-term care / welfare	Δ450	Δ161	Δ94	26
Other	60	24	25	23
Adjustment	22	29	29	29
<b>Ordinary profits</b>	<b>5,184</b>	<b>3,154</b>	<b>3,939</b>	<b>4,634</b>
<b>Net income</b>	<b>2,425</b>	<b>1,854</b>	<b>2,517</b>	<b>3,064</b>
<b>Dividends per share</b>	<b>35</b>	<b>35</b>	<b>38</b>	<b>47</b>

## Capital allocation



## Shareholder Returns Policy

### Dividend payout ratio

To optimize our balance sheet in order to achieve our ROE targets

Set a dividend payout ratio of 100% during the period of the medium-term management plan

### ROE target

FY2024.12

ROE

11.8%

At the end of the medium-term management plan period

ROE target

17%

### Review of Directors' Compensation System

In order to further promote value sharing with shareholders and investors, in addition to the conventional restricted stock system, we plan to introduce a new performance-based stock compensation system with the KPI of achieving the goals of the medium-term management plan.

# Fiscal Year Forecast

## FY2025.12

Although sales of Online eligibility verification related options for fy 2024 exceeded expectations, we have not changed our earnings forecast from the mid-term management plan disclosed on November 14, 2024 due to the end of intensive demand in fy 2025.


Accelerated introduction of Electronic Prescriptions is expected to range from subsidies to Q1 due to the impact of the addition of the system to promote dx in the medical field.

In addition, although there are also welfare administrative responses by Public Medical Hub:PMH, which connects local governments and medical institutions, it is assumed to be an additional factor, incorporating a minimum as a prerequisite for planning

Units:Millions of yen

	FY2024.12 Results	FY2025.12 Full Year Forecast
<b>Sales</b>	<b>24,837</b>	<b>21,740</b>
Pharmacies	20,699	17,798
Clinics	2,564	2,321
Long-term care/welfare	570	677
Others	1,174	1,120
Adjustment	△ 171	△178
<b>Operating Profits</b>	<b>4,464</b>	<b>2,522</b>
Pharmacies	5,255	3,062
Clinics	△ 423	△431
Long-term care/welfare	△ 450	△161
Others	60	24
Adjustment	22	29
<b>Ordinary profits</b>	<b>5,184</b>	<b>3,154</b>
<b>Net income</b>	<b>2,425</b>	<b>1,854</b>


# Changes in Consolidate Results by Fiscal Year



# Shareholder Returns

# Shareholder Returns (Dividends)

FY2024 dividend increased by 6 yen from the time of revision of the Q3 forecast to 26 yen  
 FY2025 dividends will also be maintained at the FY2024 dividend level, leaving a full-year dividend of 35 yen.



\*We conducted stock splits on April 1st, 2016 and March 1st, 2018 and January 1st, 2020 at a ratio of two shares per one ordinary share.  
 The above figures are based on the assumption that the respective stock splits were conducted at the beginning of the fiscal year.

# Acquisition and retirement of treasury stock

We have been acquiring treasury stock as a strategic means of improving capital efficiency and enhancing shareholder returns. We will continue to consider shareholder returns, including acquisition of treasury stock, in order to continuously increase the corporate value of each share.

Acquisition period	Total acquisition value	Percentage of total shares issued
November 10, 2010 ~	57 million yen	1.14%
February 09, 2011 ~	69 million yen	1.18%
September 05, 2011 ~	79 million yen	1.26%
November 11, 2011 ~	77 million yen	1.08%
May 25, 2015 ~	99 million yen	0.49%
June 18, 2018 ~	500 million yen	1.19%
January 07, 2019 ~	500 million yen	1.18%
June 11, 2020 ~	500 million yen	0.78%
February 10, 2022 ~	500 million yen	0.80%
February 15, 2024 ~	1 billion yen	2.31%

Retirement of treasury stock

Total number of shares cancelled: 4,000,000 shares

(Ratio in relation to the total number of shares issued before cancellation 5.37%)

Cancellation date: December 16, 2024

\*1 Excluding treasury stock


\*2 Rounded to the third decimal place



# Appendix.

# M&A Performance (Track Record and Effectiveness)

- 7 M&As since 2013 to increase market share in the dispensing market and to acquire customers as a foundation for entering new markets
- We intend to continue identifying market changes and responding flexibly in order to expand our customer base in the pharmacy, clinic, and long-term care/welfare fields, and to improve our product lineup and quality



## Pharmacies

Number of customers : 8,000  
Contributions to higher retention and ARPU by enhancing services such as those relating to electronic drug history records

## Clinics

Number of customers : 1,700  
Conclusion of M&As that contribute to the expansion of our base, including the expansion of sales channels

## long-term care/welfare

Number of Licenses : 11,000  
Acquisition of product development resources, etc. to expand into the long-term care/welfare market

	Units: Millions of yen			
	FY2023.12	FY2024.12	Change	Percentage Change
<b>Assets</b>	29,387	31,669	2,282	7.8%
Current assets	14,800	18,349	3,549	24.0%
Fixed assets	14,587	13,320	△1,266	△8.7%
Tangible fixed assets	1,330	1,241	△88	△6.7%
Intangible fixed assets	5,186	3,494	△1,691	△32.6%
Investments and other assets	8,070	8,584	513	6.4%
<b>Liabilities</b>	8,821	11,050	2,228	25.3%
Current liabilities	5,618	9,072	3,454	61.5%
Fixed liabilities	3,202	1,977	△1,225	△38.3%
<b>Net assets</b>	20,566	20,619	53	0.3%
Shareholder's equity	20,272	20,320	48	0.2%
Cumulative amount of other comprehensive	191	213	21	11.2%
Stock acquisition rights	56	55	0	△1.4%
Non-controlling interests	45	29	△15	△34.6%

# By Segment Sales Breakdown


Units : Millions of yen

	FY2023.12 Results	FY2024.12 Results	YoY change	YoY % change
<b>Net Sales</b>	20,355	24,837	4,481	22.0%
<b>IT Systems for Pharmacies</b>	16,159	20,699	4,539	28.1%
Initial	7,441	10,812	3,371	45.3%
System usage fee	5,840	6,961	1,120	19.2%
Consumable goods	1,954	2,069	115	5.9%
Maintenance service	923	855	△68	△7.4%
<b>IT Systems for Clinics</b>	2,802	2,564	△238	△8.5%
Initial	1,731	1,592	△138	△8.0%
System usage fee	840	805	△35	△4.2%
Consumable goods	61	54	△7	△11.7%
Maintenance service	169	112	△57	△33.6%
<b>IT Systems for Long-term care/welfare</b>	550	570	19	3.5%
Initial	37	101	63	170.2%
System usage fee	232	237	4	2.1%
Consumable goods	0	0	0	-
Maintenance service	280	231	△49	△17.6%
<b>Other Businesses</b>	973	1,174	200	20.6%
<b>Adjustments</b>	△131	△171	△39	-

\* Net sales by segment are the amounts before elimination of inter-segment transactions

# Quarterly Sales (Pharmacies)


Units: millions of yen



	FY2020			FY2021				FY2022				FY2023				FY2024			
	Q1	Q2	Q3	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Initial sales	629	1,006	942	860	938	1,265	1,502	1,458	1,586	1,711	1,719	2,016	1,840	1,877	1,706	2,099	1,965	3,275	3,473
Supply & maintenance sales	614	621	659	622	650	631	667	621	664	640	704	617	654	769	835	754	756	703	710
System usage fee sales	988	994	996	1,004	1,022	1,019	1,042	1,068	1,100	1,122	1,130	1,149	1,403	1,624	1,663	1,714	1,723	1,741	1,782

# Quarterly Sales(Clinics)


Units: millions of yen



	FY2020			FY2021				FY2022				FY2023				FY2024			
	Q1	Q2	Q3	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Initial sales	148	230	187	206	199	250	265	274	267	285	307	521	473	453	282	327	336	393	535
Supply & maintenance sales	90	86	72	82	80	76	76	72	69	65	68	64	56	53	55	48	42	39	36
System usage fee sales	154	163	165	172	177	180	187	191	197	198	203	205	206	213	215	219	223	209	152

# Quarterly Sales (Long-term care/welfare)


Units: millions of yen



	FY2020			FY2021				FY2022				FY2023				FY2024			
	Q1	Q2	Q3	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Initial sales	10	8	19	49	16	8	10	13	7	7	12	12	8	10	6	11	26	47	16
Supply & maintenance sales	77	76	78	77	77	75	75	76	75	74	72	73	72	68	67	65	56	57	54
System usage fee sales	31	38	39	40	41	42	44	46	48	51	52	55	57	59	60	62	62	58	52

# By Segment Recurring Income Business (Quarterly Sales)

Units: millions of yen



	FY2020			FY2021				FY2022				FY2023				FY2024			
	Q1	Q2	Q3	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Recurring income business for Pharmacy	1,602	1,615	1,655	1,626	1,672	1,650	1,709	1,689	1,764	1,762	1,835	1,766	2,057	2,394	2,499	2,469	2,479	2,444	2,492
Recurring income business for Clinics	244	249	237	254	257	256	263	263	266	263	271	270	263	266	270	268	265	248	188
Recurring income business for Long-term care/welfare	108	114	117	117	118	117	119	122	123	125	125	128	130	127	127	127	118	116	106




# Our Share and Our Approach to Expanding Our Share

While each market continues to consolidate around the top manufacturers, there are still many mid-sized vendors with several thousand customers

Vendors with 10,000 or fewer customers bear a heavy burden when developing systems in response to revisions


Our intention is to increase our share of each market by continuing to actively pursue M&As

## IT Systems for Pharmacies




Number of customers: 24,170 (QoQ+15)  
Target population: 55,000

## IT Systems for Clinics



Number of customers: 3,209 (QoQ+51)  
Target population: 90,000

## IT Systems for Long-term care/welfare




Number of customers: 14,208 (QoQ  $\Delta$ : 154)  
Target population: 290,000

(As of December 31, 2024)


## IT Systems for Pharmacies

Units: locations




## IT Systems for Clinics


Units: locations



## IT Systems for Long-term care/welfare

Unit: licenses





## Online Eligibility Verification


### Obligation

- Application and installation largely complete


## Electronic Prescriptions

### Recommendation

- Applications and installations are gradually being made




# How the Online Eligibility Verification System Works



# How Electronic Prescriptions Function

Electronic prescriptions are a system for managing prescriptions electronically. It enables users to refer to the latest prescription and dispensing information at multiple medical institutions and pharmacies, and to check for duplicate medications.



- **Human Capital-related Initiatives**

- Expand recruitment activities
- Full-scale operation of human resource education and training system development
- Provision of opportunities to self-enhance skills (e-Learning)

- **Set long-term goals (KPIs) based on materiality**

- Established 18 long-term goals through 2030, including "Improve Employee Engagement Score"
- The Sustainability Committee will review the status of achievement and goals

Disclose details of initiatives and progress in achieving targets in annual reports and on sustainability website. ([Link](#))

## External Evaluation

- Recognized as an Excellent Corporation for Health & Productivity Management 2024
- Recognized as 3.5 stars in the Nikkei Sustainable Comprehensive Survey for Smart Work Management
- S&P/JPX Carbon Efficient Index: First selection: continued authorization
- FTSE Blossom Japan Sector Relative Index: continued authorization



FTSE Blossom  
Japan Sector  
Relative Index

## Support for tennis academies and professional tennis players

Support for the Tennis Academy [Ai Love All Tennis Academy]

Affiliation contract with professional tennis players

Provision of [EM Tennis Clinic] for medical practitioners (2024 in Fukuoka and Kanto)



Imamura Pro, EM Systems

2024 All-Japan Champion singles best 4 and doubles semi-winners

W15 Singles champion 2 times

W15 Doubles champion

W50 Doubles champion

2024  
EM Tennis Clinic in Kanto  
By many medical practitioners  
You enjoyed participating!



Saki Imamura



## Research Support Activities

- **Donations to Medical AI/Digital Twin Development Course (Course head: Specially-appointed Assistant Professor Yoshimasa Kawazoe M.D., Ph.D.)**  
With the goal of developing a foundation for new medical services based on AI and ICT [University of Tokyo's Course on Artificial Intelligence in Healthcare] endorses the purpose of its activities, and donations to the course were started in 2017.  
From fiscal 2023, we plan to continue contributing to the research and development of this course in support of the establishment of the "Medical AI/Digital Twin Development Course", which is an extension of this course.
- **Participation in examination of next-generation electronic medical record base (Representative: Professor Kazuhiko Ohe, M.D., Ph.D. at the University of Tokyo)**  
We participate in the activities of [NeXEHRs], which was established with the goal of constructing a next-generation electronic medical record sharing platform.  
Activities of the Next-Generation Common PF and the Working Group to Consider Cooperation with the IoT and AI
- **Support for polypharmacy measures (Representative: Professor Hirohisa Imai Ph.D. at the University of Teikyo)**  
We agree with the purpose of the polypharmacy measures promoted by the Society for the Promotion of Proper Drug Usage, and we support its activities as a special member.
- **Participation in PHR proliferation activities (Representative: Professor Taku Iwami Ph.D. at Kyoto University)**  
With the aim of promoting the appropriate proliferation of Personal Health Records (PHR) and contributing to further improving health and safety  
A system for participating in the activities of the [PHR Promotion Council], and for utilizing data relating to medical care, long-term care, health, etc. at the discretion of the individual concerned  
Support the proliferation

## Supporting Activities

- **Participation in the Cross-ministerial Strategic Innovation Promotion Program (SIP) (Cabinet Office)**  
With the [Council for Science, Technology and Innovation] of the Cabinet Office serving as the headquarters for initiatives from basic research to practical applications and commercialization  
As a cooperating organization in [the construction of an integrated healthcare system] in the third phase, which began from FY2023, of the program to be promoted (SIP)  
Participated in formulating specifications for the core functions of [cloud-based standardized electronic medical record]
- **Advance implementation of online eligibility verification and electronic prescriptions (Ministry of Health, Labour and Welfare)**  
In response to a request for cooperation from the Ministry of Health, Labour and Welfare, in four regions in Japan (Sakata, Yamagata Prefecture; Sugakawa, Fukushima Prefecture; Asahi, Chiba Prefecture; and Asa, Hiroshima Prefecture) from October 2022  
Participated in the Electronic Prescriptions Model Project, under which Electronic Prescriptions services are to be launched in advance  
Continued project for advance implementation of new features for online eligibility verification and electronic prescription systems after November 2023.

## Donation activities

- **Commencement of acceptance of donations of EM Online Shop points (Japanese Red Cross Society and WFP)**  
Addition of a donation item to the conversion destination of points granted to customers based on the purchase amounts of supplies and consumables.  
10% of the donation amount added to the total by the Company following compilation of data.



# #TX | Thanks Transformation

医療・介護を「#ありがとう」に変えていく

The contents in this presentation materials are based on assumptions judged to be valid and information available to the Company's management at the time they were prepared.

Based on. The Company assumes no obligation to update or revise any information, whether as a result of new information, future events or otherwise.

As forecasts contained herein are based on assumptions of numerous uncertain factors,

Actual results may differ significantly from these forecasts for a number of reasons.

EM SYSTEMS CO., LTD. IR Section

Inquiries: <https://emsystems.co.jp/ir/mailform.html>